Aggregate Risk Score Based on Markers of Inflammation, Cell Stress, and Coagulation Is an Independent Predictor of Adverse Cardiovascular Outcomes

Emory University School of Medicine, Department of Medicine, Division of Cardiology. Atlanta, GA.
Journal of the American College of Cardiology (Impact Factor: 16.5). 05/2013; 62(4). DOI: 10.1016/j.jacc.2013.03.072
Source: PubMed


OBJECTIVE: To determine an aggregate, pathway- specific risk score for enhanced prediction of death and myocardial infarction (MI). BACKGROUND: Activation of inflammatory, coagulation, and cellular stress pathways contribute to atherosclerotic plaque rupture. We hypothesized that an aggregate risk score comprised of biomarkers involved in these different pathways--high sensitivity C-reactive protein (CRP), fibrin degradation products (FDP), and heat shock protein 70 (HSP70) levels--would be a powerful predictor of death and MI. METHODS: Serum levels of CRP, FDP and HSP70 were measured in 3,415 consecutive patients with suspected or confirmed CAD undergoing cardiac catheterization. Survival analyses were performed with models adjusted for established risk factors. RESULTS: Median follow-up was 2.3 years. Hazard ratios (HRs) for all-cause death and MI based on cut-points were as follows: for CRP ≥3.0 mg/L, HR=1.61HSP70 >0.625 ng/mL, HR= 2.26; and FDP ≥1.0 μg/ml, HR=1.62 (p <0.0001 for all). An aggregate biomarker score between 0 and 3 was calculated based on these cut-points. Compared to the group with 0 score, HRs for all-cause death and MI were 1.83, 3.46, and 4.99 for those with scores of 1, 2, and 3, respectively (p for each: <0.001). Annual event rates were 16.3% for the 4.2% of subjects with a score of 3 compared to 2.4% in 36.4% subjects with a score of 0. The C-Statistic and Net Reclassification improved (p<0.0001) with the addition of the biomarker score. CONCLUSIONS: An aggregate score based on serum levels of CRP, FDP and HSP70 is a predictor of future risk of death and MI in patients with suspected or known CAD.

Download full-text


Available from: Ravi Prasad Avati Nanjundappa, Aug 25, 2015
  • Source
    • "The replication cohort was a nested study within the Emory Cardiovascular Biobank with subjects enrolled between years 2008e2011. Demographics, medical, and behavioral characteristics as well as risk factor prevalence were documented as previously described [10]. Subjects were classified as current or non-smokers. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Stromal derived factor-1α/CXCL12 is a chemoattractant responsible for homing of progenitor cells to ischemic tissues. We aimed to investigate the association of plasma CXCL12 with long-term cardiovascular outcomes in patients with coronary artery disease (CAD). Methods: 785 patients aged: 63 ± 12 undergoing coronary angiography were independently enrolled into discovery (N = 186) and replication (N = 599) cohorts. Baseline levels of plasma CXCL12 were measured using Quantikine CXCL12 ELISA assay (R&D systems). Patients were followed for cardiovascular death and/or myocardial infarction (MI) for a mean of 2.6 yrs. Cox proportional hazard was used to determine independent predictors of cardiovascular death/MI. Results: The incidence of cardiovascular death/MI was 13% (N = 99). High CXCL12 level based on best discriminatory threshold derived from the ROC analysis predicted risk of cardiovascular death/MI (HR = 4.81, p = 1 × 10(-6)) independent of traditional risk factors in the pooled cohort. Addition of CXCL12 to a baseline model was associated with a significant improvement in c-statistic (AUC: 0.67-0.73, p = 0.03). Addition of CXCL12 was associated with correct risk reclassification of 40% of events and 10.5% of non-events. Similarly for the outcome of cardiovascular death, the addition of the CXCL12 to the baseline model was associated with correct reclassification of 20.7% of events and 9% of non-events. These results were replicated in two independent cohorts. Conclusion: Plasma CXCL12 level is a strong independent predictor of adverse cardiovascular outcomes in patients with CAD and improves risk reclassification. Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.
    Full-text · Article · Oct 2014 · Atherosclerosis
  • Source
    • "Clinical characteristics and behavioral factors were obtained using a comprehensive questionnaire and were confirmed by electronic chart review. Risk factor prevalence was determined by physician diagnosis and/or treatment of hypertension, hyperlipidemia, and diabetes and detailed medication history was obtained [15]. Prevalent myocardial infarction (MI) at the time of enrollment was diagnosed using standard universal criteria. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Genetic risk scores have been developed for coronary artery disease and atherosclerosis, but are not predictive of adverse cardiovascular events. We asked whether peripheral blood expression profiles may be predictive of acute myocardial infarction (AMI) and/or cardiovascular death. Methods Peripheral blood samples from 338 subjects aged 62 ± 11 years with coronary artery disease (CAD) were analyzed in two phases (discovery N = 175, and replication N = 163), and followed for a mean 2.4 years for cardiovascular death. Gene expression was measured on Illumina HT-12 microarrays with two different normalization procedures to control technical and biological covariates. Whole genome genotyping was used to support comparative genome-wide association studies of gene expression. Analysis of variance was combined with receiver operating curve and survival analysis to define a transcriptional signature of cardiovascular death. Results In both phases, there was significant differential expression between healthy and AMI groups with overall down-regulation of genes involved in T-lymphocyte signaling and up-regulation of inflammatory genes. Expression quantitative trait loci analysis provided evidence for altered local genetic regulation of transcript abundance in AMI samples. On follow-up there were 31 cardiovascular deaths. A principal component (PC1) score capturing covariance of 238 genes that were differentially expressed between deceased and survivors in the discovery phase significantly predicted risk of cardiovascular death in the replication and combined samples (hazard ratio = 8.5, P < 0.0001) and improved the C-statistic (area under the curve 0.82 to 0.91, P = 0.03) after adjustment for traditional covariates. Conclusions A specific blood gene expression profile is associated with a significant risk of death in Caucasian subjects with CAD. This comprises a subset of transcripts that are also altered in expression during acute myocardial infarction.
    Full-text · Article · May 2014 · Genome Medicine
  • Source
    • "The scores improved accuracy of clinical algorithms for global cardiovascular risk prediction that reclassified subjects at intermediate-risk into higher- or lower-risk categories. Another score based on serum levels of CRP, fibrin degradation products, and heat shock protein 70 as predictors of future risk of death and myocardial infarction in patients with suspected or known CHD followed in 2013 [34]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: C-reactive protein (CRP) and coronary heart disease (CHD) have been the subject of intensive investigations over the last decades. Epidemiological studies have shown an association between moderately elevated CRP levels and incident CHD whereas genetic studies have shown that polymorphisms associated with elevated CRP levels do not increase the risk of ischemic vascular disease, suggesting that CRP might be a bystander rather than a causal factor in the progress of atherosclerosis. Beside all those epidemiological and genetic studies, the experimental investigations also try to reveal the role of CRP in the progress of atherosclerosis. This review will highlight the complex results of genomic, epidemiological, and experimental studies on CRP and will show why further studies investigating the relationship between CRP and atherosclerosis might be needed.
    Full-text · Article · Apr 2014 · Mediators of Inflammation
Show more